Current Trends and Future Perspectives in the Treatment of Pulmonary Hypertension: WHO Group II-V

Curr Probl Cardiol. 2018 May;43(5):217-231. doi: 10.1016/j.cpcardiol.2017.10.003. Epub 2017 Oct 31.

Abstract

Pulmonary hypertension continues to be a life-threatening illness with debilitating physical and emotional consequences affecting around 1% of global population. The progression of this devastating disease is characterized by increase in pulmonary vascular resistance resulting in elevated pulmonary pressure, eventually leading to right heart failure and death. Better understanding of pathophysiology has led to substantial improvements in terms of availability of treatment options. The purpose of this review is to summarize the currently available treatment options along with pertinent trials and possible future therapies of pulmonary hypertension group II-V.

Publication types

  • Review

MeSH terms

  • Antihypertensive Agents / therapeutic use*
  • Global Health
  • Guideline Adherence*
  • Humans
  • Hypertension, Pulmonary* / drug therapy
  • Hypertension, Pulmonary* / epidemiology
  • Hypertension, Pulmonary* / physiopathology
  • Morbidity / trends
  • Pulmonary Wedge Pressure / physiology*
  • World Health Organization

Substances

  • Antihypertensive Agents